UY40815A - Bloqueadores de canales de sodio - Google Patents
Bloqueadores de canales de sodioInfo
- Publication number
- UY40815A UY40815A UY0001040815A UY40815A UY40815A UY 40815 A UY40815 A UY 40815A UY 0001040815 A UY0001040815 A UY 0001040815A UY 40815 A UY40815 A UY 40815A UY 40815 A UY40815 A UY 40815A
- Authority
- UY
- Uruguay
- Prior art keywords
- sodium channel
- channel blockers
- modulate
- disorders
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
Abstract
La presente divulgación se refiere a compuestos de sulfonamida, a su uso para modular el canal de sodio Nav1.5, y a métodos para tratar o prevenir enfermedades, trastornos o afecciones usando los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023106400 | 2023-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY40815A true UY40815A (es) | 2025-01-15 |
Family
ID=94214640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040815A UY40815A (es) | 2023-07-07 | 2024-07-05 | Bloqueadores de canales de sodio |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20250034108A1 (es) |
| EP (1) | EP4739669A1 (es) |
| JP (1) | JP2026524110A (es) |
| KR (1) | KR20260035224A (es) |
| CN (1) | CN121548572A (es) |
| AR (1) | AR133184A1 (es) |
| AU (1) | AU2024296422A1 (es) |
| CL (1) | CL2026000001A1 (es) |
| CO (1) | CO2025019045A2 (es) |
| CR (1) | CR20250551A (es) |
| DO (1) | DOP2025000336A (es) |
| IL (1) | IL325153A (es) |
| MX (1) | MX2026000100A (es) |
| TW (1) | TW202502310A (es) |
| UY (1) | UY40815A (es) |
| WO (1) | WO2025011450A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007021941A2 (en) * | 2005-08-16 | 2007-02-22 | Icagen, Inc. | Inhibitors of voltage-gated sodium channels |
| ES2586213T3 (es) * | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| WO2017201468A1 (en) * | 2016-05-20 | 2017-11-23 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP3551626B1 (en) * | 2016-12-09 | 2023-10-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| TW202003490A (zh) * | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| US10981905B2 (en) * | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
| MA53488A (fr) * | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| CN110885319B (zh) * | 2018-09-10 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
-
2024
- 2024-07-05 AR ARP240101762A patent/AR133184A1/es unknown
- 2024-07-05 CR CR20250551A patent/CR20250551A/es unknown
- 2024-07-05 UY UY0001040815A patent/UY40815A/es unknown
- 2024-07-05 KR KR1020267003328A patent/KR20260035224A/ko active Pending
- 2024-07-05 EP EP24838703.7A patent/EP4739669A1/en active Pending
- 2024-07-05 TW TW113125258A patent/TW202502310A/zh unknown
- 2024-07-05 US US18/764,471 patent/US20250034108A1/en active Pending
- 2024-07-05 IL IL325153A patent/IL325153A/en unknown
- 2024-07-05 AU AU2024296422A patent/AU2024296422A1/en active Pending
- 2024-07-05 JP JP2026500008A patent/JP2026524110A/ja active Pending
- 2024-07-05 WO PCT/CN2024/103810 patent/WO2025011450A1/en not_active Ceased
- 2024-07-05 CN CN202480043334.9A patent/CN121548572A/zh active Pending
-
2025
- 2025-12-29 DO DO2025000336A patent/DOP2025000336A/es unknown
- 2025-12-30 CO CONC2025/0019045A patent/CO2025019045A2/es unknown
-
2026
- 2026-01-02 CL CL2026000001A patent/CL2026000001A1/es unknown
- 2026-01-07 MX MX2026000100A patent/MX2026000100A/es unknown
- 2026-02-09 US US19/534,025 patent/US20260167617A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR133184A1 (es) | 2025-09-03 |
| AU2024296422A1 (en) | 2025-12-18 |
| WO2025011450A1 (en) | 2025-01-16 |
| EP4739669A1 (en) | 2026-05-13 |
| DOP2025000336A (es) | 2026-03-15 |
| CR20250551A (es) | 2026-01-19 |
| CN121548572A (zh) | 2026-02-17 |
| CL2026000001A1 (es) | 2026-04-06 |
| WO2025011450A9 (en) | 2026-01-15 |
| US20250034108A1 (en) | 2025-01-30 |
| TW202502310A (zh) | 2025-01-16 |
| CO2025019045A2 (es) | 2026-01-23 |
| KR20260035224A (ko) | 2026-03-12 |
| JP2026524110A (ja) | 2026-07-17 |
| IL325153A (en) | 2026-02-01 |
| US20260167617A1 (en) | 2026-06-18 |
| MX2026000100A (es) | 2026-03-02 |